Monday, April 21, 2014

FDA Safety Warning for Laparoscopic Uterine Morcellation

Just last week, the FDA issued a communication about the possible dangers of Laparoscopic Uterine Power Morcellation for hysterectomy and myomectomy. This process is typically used to perform minimally invasive hysterectomys and to remove uterine fibroids (myomectomy). Morcellation divides the tissue that is being removed into smaller pieces so that they can be easily extracted though a small incision. However, it is estimated that about 1 in 350 women will have an undetected cancerous sarcoma when receiving this treatment, which may cause the cancer to spread to other parts of the lower body. The FDA therefore discourages the use of this treatment for women with fibroids. 

Physicians are advised not to use this type of treatment, especially for women with known or suspected uterine cancer. It is important to discuss in detail, all treatment options with patients who have uterine fibroids. Patients are encouraged to ask questions about the risk and benefits associated with all treatment options. If this is a procedure you have already had done and your removed cells tested negative for cancer, it is recommenced that you have a routine follow-up with your healthcare provider. 


Laparoscopic Uterine Power Morcellation in Hysterectomy and Myomectomy: FDA Safety Communication

Information on Uterine Sarcoma

Uterine Fibroids Factsheet


  1. Journal of Women's Health & Safety Research is an online international open access journal aims to promote the health and healthcare for women throughout their lifespan. The Journal delivers cutting-edge advancements on the prevention, diagnosis and management of issues related to women health and safety in diverse communities.
    Women's Health & Safety Research